← Back to Search

CHaRRM Counseling for Opioid Use Disorder (CHaRRM-CN Trial)

N/A
Recruiting
Led By Ashley Lincoln, MSW
Research Sponsored by Washington State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 1, month 3, month 6
Awards & highlights

Summary

This trial tests a culturally adapted counseling program called CHaRRM-CN for American Indian individuals with opioid addiction. The program aims to help them stay in treatment longer, reduce substance-related harm, and strengthen their connection to Native culture.

Who is the study for?
This trial is for adults over 18 who are new to the Cherokee Nation Health Services Medication-assisted Treatment (MAT) Program or returning after a six-month break. They must be able to understand and agree to the study's terms. People can't join if they're unable to consent or pose a risk to others' safety.
What is being tested?
The trial tests CHaRRM-CN, a program aiming to improve patient retention in MAT, reduce opioid-related harm, and boost cultural ties within the Cherokee Nation. Participants will either receive this new counseling approach or standard treatment for comparison.
What are the potential side effects?
Since this trial focuses on counseling methods rather than medication, traditional side effects like those seen with drugs aren't expected. However, participants may experience emotional discomfort discussing substance use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 1, month 3, month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 1, month 3, month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MAT retention
Secondary study objectives
ED visits
Illicit Opioid Use
Native enculturation
+2 more
Other study objectives
Health-related quality of life (HR-QoL)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CHaRRM-CNExperimental Treatment1 Intervention
The CHaRRM-CN condition comprises changes and additions to TAU codesigned with a community advisory board and taking into account suggestions from MAT patients and community members impacted by OUD with the goal of improving MAT retention in culturally aligned and community-driven ways.
Group II: Treatment as Usual (TAU)Active Control1 Intervention
The TAU condition will entail the current CNHS MAT program for OUD.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Opioid Use Disorder (OUD) include Medication-Assisted Treatment (MAT) and psychosocial interventions. MAT uses medications like methadone, buprenorphine, or naltrexone to normalize brain chemistry, block euphoric effects, and relieve cravings. Psychosocial interventions, such as Cognitive Behavioral Therapy (CBT), Contingency Management, and Motivational Interviewing, address the psychological and social aspects of addiction. The CHaRRM-CN trial emphasizes harm reduction and cultural connectedness, enhancing treatment relevance and effectiveness by aligning it with patients' cultural values. This holistic approach is crucial for improving treatment retention and reducing relapse risk.
Mindfulness-Based Intervention Effects on Substance Use and Relapse Among Women in Residential Treatment: A Randomized Controlled Trial With 8.5-Month Follow-Up Period From the Moment-by-Moment in Women's Recovery Project.Efficacy and mechanisms of a single-session behavioral medicine class among patients with chronic pain taking prescription opioids: study protocol for a randomized controlled trial.A Process Evaluation of a Substance Use Brief Intervention for Adolescents in a Psychiatric Inpatient Program.

Find a Location

Who is running the clinical trial?

Washington State UniversityLead Sponsor
105 Previous Clinical Trials
57,238 Total Patients Enrolled
University of WashingtonOTHER
1,805 Previous Clinical Trials
1,912,585 Total Patients Enrolled
Cherokee Nation Health ServicesUNKNOWN
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

CHaRRM-CN Clinical Trial Eligibility Overview. Trial Name: NCT05733442 — N/A
Opioid Use Disorder Research Study Groups: Treatment as Usual (TAU), CHaRRM-CN
Opioid Use Disorder Clinical Trial 2023: CHaRRM-CN Highlights & Side Effects. Trial Name: NCT05733442 — N/A
CHaRRM-CN 2023 Treatment Timeline for Medical Study. Trial Name: NCT05733442 — N/A
~52 spots leftby Jun 2025